HIV-1 Gp120 Compromises Blood-brain Barrier Integrity and Enhances Monocyte Migration Across Blood-brain Barrier: Implication for Viral Neuropathogenesis
Overview
Endocrinology
Neurology
Authors
Affiliations
Human immunodeficiency virus-1 (HIV-1) encephalitis is characterized by brain infiltration of virus-infected monocytes and macrophages. Cellular products and viral proteins secreted by infected cells likely play an important role in blood-brain barrier (BBB) impairment and the development of HIV-1-associated dementia (HAD). We previously demonstrated that HIV-1 envelope glycoprotein gp120 induces toxicity and alters expression of tight junction proteins in human brain microvascular endothelial cells (HBMECs). Here, we delineate the mechanisms of gp120-induced BBB dysfunction. Human brain microvascular endothelial cells expressed HIV-1 co-receptors (CCR5 and CXCR4). Exposure of HBMECs to gp120 derived from macrophage (CCR5) or lymphocyte (CXCR4)-tropic viruses decreased BBB tightness, increased permeability, and enhanced monocyte migration across in vitro BBB models. Blood-brain barrier integrity was restored after gp120 removal. CCR5 antibodies and inhibitors of myosin light chain kinase or protein kinase C (PKC) blocked gp120-enhanced monocyte migration and permeability of BBB in vitro. Exposure of HBMECs to gp120 induced release of intracellular calcium ([Ca(2+)](i)) that was prevented by CCR5 antibody and partially blocked by CXCR4 antagonist. Human immunodeficiency virus-1 gp120 activated three PKC isoforms in HBMECs [PKC-alpha/betaII, PKC(pan)-betaII and PKC-zeta/lambda]. Furthermore, specific PKC inhibitors (acting at the ATP-binding and calcium release site) blocked gp120-induced PKC activation and prevented increase in BBB permeability, supporting the biologic significance of these results. Thus, gp120 can cause dysfunction of BBB via PKC pathways and receptor mediated [Ca(2+)](i) release leading to cytoskeletal alterations and increased monocyte migration.
Kelly S, Nightingale S, Gupta R, Collier D Trop Med Infect Dis. 2025; 10(2).
PMID: 39998049 PMC: 11860496. DOI: 10.3390/tropicalmed10020045.
Galpayage Dona K, Benmassaoud M, Gipson C, McLaughlin J, Ramirez S, Andrews A NeuroImmune Pharm Ther. 2025; 3(2):97-111.
PMID: 39958876 PMC: 11823645. DOI: 10.1515/nipt-2024-0003.
Beard Jr R, Hoettels B, McAllister J, Meegan J, Wertz T, Self D J Cereb Blood Flow Metab. 2025; :271678X251318620.
PMID: 39917847 PMC: 11806455. DOI: 10.1177/0271678X251318620.
The Impact of HIV on Early Brain Aging-A Pathophysiological (Re)View.
Lazar M, Moroti R, Barbu E, Chitu-Tisu C, Tiliscan C, Erculescu T J Clin Med. 2024; 13(23).
PMID: 39685490 PMC: 11642420. DOI: 10.3390/jcm13237031.
Annadurai N, Kanmogne G Cells. 2024; 13(17.
PMID: 39272987 PMC: 11393916. DOI: 10.3390/cells13171415.